systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-751Research ArticleСТАТЬИARTICLESВозможности дигидропиридинового блокатора кальциевых каналов фелодипина в обеспечении органопротекции и снижении риска сердечно-сосудистых осложнений у больных артериальной гипертензиейЧихладзеН. М.noemail@neicon.ruИКК им. А.Л.Мясникова ФГБУ РКНПК Минздрава РФ, МоскваRussian Federation201209022023931822Copyright © Чихладзе Н.М., 20232023Чихладзе Н.М.Чихладзе Н.М.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/751ReferencesGhali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998; 31: 1635-40.Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998; 31: 1635-40.O'Leary DH, Polak JF, Kronmal RA. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.O'Leary DH, Polak JF, Kronmal RA. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96 (5):1432-7.Bots ML, Hoes AW, Koudstaal PJ et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96 (5):1432-7.Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (4-й пересмотр). Системные гипертензии 2010; 3: 5-26.Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (4-й пересмотр). Системные гипертензии 2010; 3: 5-26.ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351 (9118): 1755-62.Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351 (9118): 1755-62.Liu L, Zhang Y, Liu G et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23 (12): 2157-72.Liu L, Zhang Y, Liu G et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23 (12): 2157-72.Zhang Y, Zhang X, Liu L et al. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J 2011; 32 (12): 1500-8.Zhang Y, Zhang X, Liu L et al. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J 2011; 32 (12): 1500-8.Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27.Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27.Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.De Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006; 17: 2100-5.De Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006; 17: 2100-5.Nalbantgil I, Onder R, Killiçcioglu B et al. The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. Blood Press 1996; 5 (5): 285-91.Nalbantgil I, Onder R, Killiçcioglu B et al. The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. Blood Press 1996; 5 (5): 285-91.Wetzchewald D, Klaus D, Garanin G et al. Regression of left ventricular hypertrophy during long-term antihypertensive treatment--a comparison between felodipine and the combination of felodipine and metoprolol. J Intern Med 1992; 231 (3): 303-8.Wetzchewald D, Klaus D, Garanin G et al. Regression of left ventricular hypertrophy during long-term antihypertensive treatment--a comparison between felodipine and the combination of felodipine and metoprolol. J Intern Med 1992; 231 (3): 303-8.Zanchetti A, Bold G, Hennig M et al. Calcium antagonist lacidipin slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-7.Zanchetti A, Bold G, Hennig M et al. Calcium antagonist lacidipin slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-7.Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J A M A 2004; 292 (18): 2217-25.Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J A M A 2004; 292 (18): 2217-25.Godfraind T. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci 2005; 360 (1464): 2259-72.Godfraind T. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci 2005; 360 (1464): 2259-72.Song H, Bao W, Wang H et al. Effects of extended-release felodipine on endothelial vasoactive substances in patients with essential hypertension. Clin Chem Lab Med 2008; 46 (3): 393-5.Song H, Bao W, Wang H et al. Effects of extended-release felodipine on endothelial vasoactive substances in patients with essential hypertension. Clin Chem Lab Med 2008; 46 (3): 393-5.Xing SS, Tan HW, Bi XP et al. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. Mol Med 2008; 14 (7-8): 395-402.Xing SS, Tan HW, Bi XP et al. Felodipine reduces cardiac expression of IL-18 and perivascular fibrosis in fructose-fed rats. Mol Med 2008; 14 (7-8): 395-402.Bi XP, Tan HW, Xing SS et al. Felodipine downregulates srum interleukin-18 levels in rats with fructose-induced metabolic syndrome. J Endocrinol Invest 2009; 32 (4): 303-7.Bi XP, Tan HW, Xing SS et al. Felodipine downregulates srum interleukin-18 levels in rats with fructose-induced metabolic syndrome. J Endocrinol Invest 2009; 32 (4): 303-7.Amenta F, Lanari A, Mignini F et al. Nicardipine use in cerebrovascular disease: a review of controlled clinical studies. J Neurol Sci 2009; 283 (1-2): 219-23.Amenta F, Lanari A, Mignini F et al. Nicardipine use in cerebrovascular disease: a review of controlled clinical studies. J Neurol Sci 2009; 283 (1-2): 219-23.Kimura Y, Kitagawa K, Oku N et al. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions. Hypertens Res 2008; 31 (12): 2147-54.Kimura Y, Kitagawa K, Oku N et al. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions. Hypertens Res 2008; 31 (12): 2147-54.Русина А.М., Мордовин В.Ф., Федоренко Е.В. и др. Сравнительный анализ гипотензивной и церебропротективной эффективности антагонистов кальция и b-блокаторов у пациентов с гипертонической болезнью и хронической гипертензивной энцефалопатией. РМЖ. 2009; 17 (1): 1-5.Русина А.М., Мордовин В.Ф., Федоренко Е.В. и др. Сравнительный анализ гипотензивной и церебропротективной эффективности антагонистов кальция и b-блокаторов у пациентов с гипертонической болезнью и хронической гипертензивной энцефалопатией. РМЖ. 2009; 17 (1): 1-5.Lehri S, Grässel E, Eicke C. Effectiveness of felodipine in hypertensive patients with mild cerebral cognition disorders in a randomized double-blind study. Dtsch Med Wochenschr 2000; 125 (45): 1350-5.Lehri S, Grässel E, Eicke C. Effectiveness of felodipine in hypertensive patients with mild cerebral cognition disorders in a randomized double-blind study. Dtsch Med Wochenschr 2000; 125 (45): 1350-5.Смоленская О.Г., Клейнер С.Л., Ставрова Н.Ю. Терапия гипертонической болезни блокаторами кальциевых каналов пролонгированного действия. Кардиология. 2004; 5: 59-62.Смоленская О.Г., Клейнер С.Л., Ставрова Н.Ю. Терапия гипертонической болезни блокаторами кальциевых каналов пролонгированного действия. Кардиология. 2004; 5: 59-62.Inzitari D, Poggesi A. Calcium channel blockers and stroke. Aging Clin Exp Res. 2005; 17 (Suppl. 4): 16-30.Inzitari D, Poggesi A. Calcium channel blockers and stroke. Aging Clin Exp Res. 2005; 17 (Suppl. 4): 16-30.Dworkin LD, Benstein JA, Parker M et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43: 808-14.Dworkin LD, Benstein JA, Parker M et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43: 808-14.Harris DCH, Hammond WS, Burke TJ. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987; 31: 41-6.Harris DCH, Hammond WS, Burke TJ. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987; 31: 41-6.Dworkin LD, Tolbert E, Recht PA. Effects of amlodipine on glomerular filtration, growth and injury in experimental hypertension. Hypertension 1996; 27: 245-50.Dworkin LD, Tolbert E, Recht PA. Effects of amlodipine on glomerular filtration, growth and injury in experimental hypertension. Hypertension 1996; 27: 245-50.Brunner FP, Bock HA, Hermle M. Control of hypertension by verapamil enhances renal damage in a rat remnant kidney model. Nephrol Dial Transplant 1991; 6: 420-7.Brunner FP, Bock HA, Hermle M. Control of hypertension by verapamil enhances renal damage in a rat remnant kidney model. Nephrol Dial Transplant 1991; 6: 420-7.Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by сalcium‐channel blockers. Nephrol Dial Transplant 1997; 12: 2244-50.Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by сalcium‐channel blockers. Nephrol Dial Transplant 1997; 12: 2244-50.Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy:an updated meta-analysis. Nephrol Dial Transplant 1995; (Suppl. 10): 39-45.Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy:an updated meta-analysis. Nephrol Dial Transplant 1995; (Suppl. 10): 39-45.Zucchelli P, Zuccala A, Borghi M et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-8.Zucchelli P, Zuccala A, Borghi M et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-8.Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood‐pressure‐lowering agents: a meta‐analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-74.Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood‐pressure‐lowering agents: a meta‐analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963-74.Mene P. Calcium channel blockers: what they can and what they can't do. Nephrol Dial Transplant 1997; 12 (1): 25-8.Mene P. Calcium channel blockers: what they can and what they can't do. Nephrol Dial Transplant 1997; 12 (1): 25-8.Herlitz H, Harris K, Risler T et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16 (11): 2158-65.Herlitz H, Harris K, Risler T et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16 (11): 2158-65.Callera GE, Montezano AC, Yogi A et al. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005; 46: 1032-8.Callera GE, Montezano AC, Yogi A et al. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005; 46: 1032-8.Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10 (2): 97-107.Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002; 10 (2): 97-107.Fritsch Neves M, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep 2003; 5 (1): 59-65.Fritsch Neves M, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep 2003; 5 (1): 59-65.Dietz JD, Du S, Bolten CW et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51: 742-8.Dietz JD, Du S, Bolten CW et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51: 742-8.Matsubara BB, Franco M, Janicki JS et al. Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. Braz J Med Biol Res 2010; 43 (5): 506-14.Matsubara BB, Franco M, Janicki JS et al. Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. Braz J Med Biol Res 2010; 43 (5): 506-14.Schaefer RM, Aldons PM, Burgess ED et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomized, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int J Clin Pract 1998; 52 (6): 381-6.Schaefer RM, Aldons PM, Burgess ED et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomized, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int J Clin Pract 1998; 52 (6): 381-6.Bicchi M, Vedovini G, Cappelli R et al. Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. Angiology 1998; 49 (5): 373-80.Bicchi M, Vedovini G, Cappelli R et al. Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. Angiology 1998; 49 (5): 373-80.Агеев Ф.Т., Фофанова Т.В., Деев А.Д. Применение фелодипина в амбулаторной практике: оценка клинической эффективности и приверженности к лечению у больных с артериальной гипертонией. Кардиология. 2009; 1: 30-3.Агеев Ф.Т., Фофанова Т.В., Деев А.Д. Применение фелодипина в амбулаторной практике: оценка клинической эффективности и приверженности к лечению у больных с артериальной гипертонией. Кардиология. 2009; 1: 30-3.
The authors declare that there are no conflicts of interest present.